✦ LIBER ✦

Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists

✍ Scribed by D Boulay; R Depoortere; Gh Perrault; E Borrelli; D.J Sanger

Book ID: 117188318
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 132 KB
Volume: 38
Category: Article
ISSN: 0028-3908
DOI: 10.1016/s0028-3908(99)00064-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity, non-selective attention and em

Activity, non-selective attention and emotionality in dopamine D2/D3 receptor knock-out mice

✍ D Vallone; M Pignatelli; G Grammatikopoulos; L Ruocco; Y Bozzi; H Westphal; E Bo 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 292 KB

Haloperidol-induced catalepsy is absent

Haloperidol-induced catalepsy is absent in dopamine D2, but maintained in dopamine D3 receptor knock-out mice

✍ Denis Boulay; Ronan Depoortere; André Oblin; David J Sanger; Hans Schoemaker; Gh 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 368 KB

Effects of dopamine receptor agonists on

Effects of dopamine receptor agonists on passive avoidance learning in mice: interaction of dopamine D1 and D2 receptors

✍ Kenji Ichihara; Toshitaka Nabeshima; Tsutomu Kameyama 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 613 KB

Differential effects of chronic dopamine

Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding

✍ Thomas M. Engber; Concepcio Marin; Zvi Susel; Thomas N. Chase 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 956 KB

The effects of dopamine and D2 receptor

The effects of dopamine and D2 receptor antagonists on pituitary hormone secretion are intact in mice lacking dopamine D2L receptor

✍ Rong Xu; Albert F. Parlow; Yanyan Wang 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Antiparkinsonian effects of the novel D3

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors

✍ Michael P. Hill; Paula Ravenscroft; Steven G. McGuire; Jonathan M. Brotchie; Ala 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

L-dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 recept